



THE POST DISCLOSURE HINDRANCE IN THE INDIAN HEALTH SCHEME

Dr. Mohd Irfan*

*SBAS, Sanskriti University,

Mathura, Uttar Pradesh, INDIA

Email id: irfan.sobas@sanskriti.edu.in

ABSTRACT

In the world more than 200,000 leprosy cases are being registered in every passing year. But the situation has changed from the past few years. In 1982 when multi-drug therapy was introduced then the leprosy cases started reducing from the popularity rate of 57.8/10000 population in 1983 to 1/10000 population in the year 2005 i.e. 296,499. Wherein the popularity state of leprosy was 219,826 in the starting of 2006 and by the year 2018 the percentage rate of leprosy reduced to 0.67/ 10, 000. Though India was highest saddle of leprosy, but with the World Health Organization instruction the National leprosy eradication programmer (NLEP) is interposing single-dose rifampicin for post-exposure prophylaxis in the entire high-autochthone localities of the nation. The main objective of this paper is to evaluate the cost-productiveness of single-dose rifampicin post-exposure prophylaxis in various leprosy ailment encumbrance circumstances. Wherein the cost-productiveness devolves on the measures by which the disability can be reduced. However, the medication is befitting cost-effective for the longer use, an everlasting perforation is being devoted.

KEYWORDS: *Leprosy, Single-dose rifampicin (SDR), Post-Exposure Prophylaxis (PEP), Cost-effective.*

REFERENCES

1. A. Tiwari, L. Mieras, K. Dhakal, M. Arif, S. Dandel, and J. H. Richardus, "Introducing leprosy post-exposure prophylaxis into the health systems of India, Nepal and Indonesia: A case study," *BMC Health Serv. Res.*, 2017, doi: 10.1186/s12913-017-2611-7.
2. A. Tiwari, D. J. Blok, M. Arif, and J. H. Richardus, "Leprosy post-exposure prophylaxis in the indian health system: A cost-effectiveness analysis," *PLoS Negl. Trop. Dis.*, 2020, doi: 10.1371/journal.pntd.0008521.
3. T. Barth-Jaeggi *et al.*, "Leprosy Post-Exposure Prophylaxis (LPEP) programme: Study protocol for evaluating the feasibility and impact on case detection rates of contact tracing and single dose rifampicin," *BMJ Open*, 2016, doi: 10.1136/bmjopen-2016-013633.
4. P. Schuetz *et al.*, "Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections," *Evidence-Based Child Heal.*, 2013, doi: 10.1002/ebch.1927.
5. J. Young *et al.*, "The rate of recovery in renal function when patients with HIV infection discontinue treatment with tenofovir," *HIV Med.*, 2014, doi: 10.1111/hiv.12149.

6. D. Stannard, "Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections," *Crit. Care Nurse*, 2014, doi: 10.4037/ccn2014559.
7. S. Prinja, A. S. Chauhan, A. Karan, G. Kaur, and R. Kumar, "Impact of publicly financed health insurance schemes on healthcare utilization and financial risk protection in India: A systematic review," *PLoS ONE*. 2017, doi: 10.1371/journal.pone.0170996.
8. S. R. Mahapatro, P. Singh, and Y. Singh, "How effective health insurance schemes are in tackling economic burden of healthcare in India," *Clin. Epidemiol. Glob. Heal.*, 2018, doi: 10.1016/j.cegh.2017.04.002.
9. S. Garg, "Universal health coverage in India: Newer innovations and the role of public health," *Indian J. Public Health*, 2018, doi: 10.4103/ijph.IJPH_221_18.
10. Pn. Rao and S. Suneetha, "Current situation of leprosy in India and its future implications," *Indian Dermatol. Online J.*, 2018, doi: 10.4103/idoj.idoj_282_17.